Alpha 2.0
Login Register
» Articles » PMID: 28443358

Cerebral Rituximab Uptake in Multiple Sclerosis: A Zr-immunoPET Pilot Study

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2017 Apr 27
PMID 28443358
Citations 9
Authors
Marloes Hj Hagens
Joep Killestein
Maqsood M Yaqub
Guus Ams van Dongen
Adriaan A Lammertsma
Frederik Barkhof
Bart Nm van Berckel
Affiliations
Soon will be listed here.
Abstract

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [Zr]rituximab.

Citing Articles

Advances and challenges in immunoPET methodology.

Mohr P, van Sluis J, Lub-de Hooge M, Lammertsma A, Brouwers A, Tsoumpas C Front Nucl Med. 2024; 4:1360710.

PMID: 39355220 PMC: 11440922. DOI: 10.3389/fnume.2024.1360710.

Persistent neuroinflammation and behavioural deficits after single mild traumatic brain injury.

Drieu A, Lanquetin A, Prunotto P, Gulhan Z, Pedron S, Vegliante G J Cereb Blood Flow Metab. 2022; 42(12):2216-2229.

PMID: 35945692 PMC: 9670002. DOI: 10.1177/0271678X221119288.

Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Thomas A, Barkhof F, Bulte J Radiology. 2022; 303(3):486-497.

PMID: 35471110 PMC: 9131169. DOI: 10.1148/radiol.211252.

Rituximab for the treatment of multiple sclerosis: a review.

Chisari C, Sgarlata E, Arena S, Toscano S, Luca M, Patti F J Neurol. 2021; 269(1):159-183.

PMID: 33416999 PMC: 7790722. DOI: 10.1007/s00415-020-10362-z.

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®.

Liapis V, Tieu W, Rudd S, Donnelly P, Wittwer N, Brown M EJNMMI Radiopharm Chem. 2020; 5(1):27.

PMID: 33205364 PMC: 7672150. DOI: 10.1186/s41181-020-00109-6.

References
1.
Piccio L, Naismith R, Trinkaus K, Klein R, Parks B, Lyons J . Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010; 67(6):707-14. PMC: 2918395. DOI: 10.1001/archneurol.2010.99. View
2.
Verel I, Visser G, Boellaard R, Stigter-van Walsum M, Snow G, van Dongen G . 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003; 44(8):1271-81. View
3.
Muylle K, Flamen P, Vugts D, Guiot T, Ghanem G, Meuleman N . Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015; 42(8):1304-14. PMC: 4480335. DOI: 10.1007/s00259-015-3025-6. View
4.
Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-88. DOI: 10.1056/NEJMoa0706383. View
5.
Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser S . Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014; 193(2):580-586. PMC: 4082756. DOI: 10.4049/jimmunol.1400118. View